Trial Profile
Repurposing Dexmedetomidine as an Orally Administered Sleep Therapeutic
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Oct 2019
Price :
$35
*
At a glance
- Drugs Dexmedetomidine (Primary)
- Indications Insomnia; Sleep disorders
- Focus Adverse reactions
- 16 Aug 2018 Status changed from recruiting to completed.
- 29 Jun 2017 Planned number of patients changed from 40 to 30.
- 26 Jan 2017 Status changed from not yet recruiting to recruiting.